For most people with epilepsy, seizures can be completely controlled by taking daily medication. However, some people still experience seizures despite taking daily medication. If these seizures recur ...

The US Food and Drug Administration (FDA) has approved diazepam nasal spray (Valtoco, Neurelis) in patients with epilepsy aged 6 and older for the acute treatment of intermittent, stereotypic episodes ...

LOS ANGELES — The definition of seizure clusters varies significantly across epilepsy monitoring units (EMUs), according to a new survey of expert opinion. The findings should prompt the development ...

Neurelis announced the availability of Valtoco® (diazepam nasal spray) for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute ...

Treatment with diazepam nasal spray resulted in a statistically significant change in time between seizure clusters, potentially reflecting a beneficial effect of intermittent rescue therapy. New post ...

Pharmacokinetic data indicate that in pediatric patients 2 to 5 years of age, administration of the buccal film is expected to provide adequate therapeutic exposures. The Food and Drug Administration ...

(BPT) - At just one day old, Spencer, born in Greenville, South Carolina, had his first seizure, a sudden, uncontrolled electrical disturbance in the brain that usually causes a change in behavior.

ATLANTA, Nov. 25, 2019 /PRNewswire/ -- UCB announced today that NAYZILAM® (midazolam) nasal spray CIV will be available in retail pharmacies on December 2, 2019, for the acute treatment of ...

Patients treated with 5-mg midazolam nasal spray were more likely than those given placebo to remain seizure free for 6 hours after treatment or have their seizure terminated within 10 minutes, with ...

Through collaborations with Le Bonheur Children’s Hospital, the Wisconsin Health Information Organization, and Yale University, UCB seeks to further understand the economic and clinical impacts of ...